{
  "docId": "019de514-f120-743f-9d00-70915b7d1fa5",
  "docSlug": "a9055659e75fd1b92a3c529616eb6953",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 49 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 49,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 50,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de514-f120-743f-9d00-70915b7d1fa5/15",
  "deckHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5",
  "deckJsonHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5.json",
  "deckAnchorHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.723,
        "x": 0.149,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "1. Products with sales outside the United States impacted by F/X changes.\n2. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.\n3. Presented on an adjusted basis after giving effect to the IPO.\n4. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f89e310-75e9-423a-a703-8e2fe336d13d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.702,
        "w": 0.853,
        "x": 0.076,
        "y": 0.166
      },
      "kind": "table",
      "text": "Bausch + Lomb FY22 FY21 Reported Change Constant Currency2 Organic Change 2,4 Vision Care Revenue $2,373M $2,343M 1% 6% 6% Surgical Revenue $718M $718M 0% 6% 8% Ophthalmic Pharmaceuticals Revenue $677M $704M (4%) 0% 0% Total Revenue $3,768M $3,765M 0% 5% 5% Gross Profit $2,004M $1,994M 1% 5% Gross Margin 53.2% 53.0% 20 bps R&D $307M $271M (13%) (16%) R&D percent of Revenues 8.1% 7.2% SG&A $1,478M $1,389M (6%) (11%) SG&A percent of Revenues 39.2% 36.9% Operating Income $207M $329M (37%) (31%) Depreciation $135M $123M 10% 15% Stock Based Compensation $62M $62M 0% 0% Net Income Attributable to Bausch + Lomb $6M $182M (97%) (103%) Net Income Margin 0.2% 4.8% EPS Attributable to Bausch + Lomb³ $0.02 $0.52",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b059ee9a-cb26-4a54-9010-247d477ad62d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.64,
        "x": 0.048,
        "y": 0.069
      },
      "kind": "title",
      "text": "Total Bausch + Lomb P&L¹ (GAAP) – FY22",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "407d96b8-986f-4c85-bda8-3d65781a2454",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "7dc62337-b2ed-4c41-8d32-808d2f972bf7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation showcases the company's strong financial performance and strategic advancements, providing satisfaction to investors",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d15671c2-99b6-48fa-89dc-6302733eef20",
      "evidence": "The presentation highlights the company's financial performance and strategic advancements, implying the consequences of not investing in Bausch + Lomb",
      "position": 0,
      "objective": "Emphasize the importance of Bausch + Lomb's solutions by highlighting the cost of inaction",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}